Overview

Optimal Treatment Strategy Based on for Pediatric AML

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Cytarabine
Etoposide
Etoposide phosphate
Idarubicin
Mitoxantrone